Cannabinoids – What Are They and How Do They Work? The Complete Guide 2026

Cannabis sativa L. is one of the most biochemically complex plants in the world. In recent years, scientists have identified over 500 chemical compounds in it, of which at least 150 are cannabinoids (PubMed, 2023). These molecules interact directly with the endocannabinoid system (ECS), a ubiquitous homeostasis regulation system found in all vertebrates.

The question "what are cannabinoids" sounds simple, but the answer goes far beyond THC and CBD. There are three main categories: phytocannabinoids from the cannabis plant, endocannabinoids produced by our bodies, and synthetic cannabinoids. Each group works differently, but all bind to CB1 and CB2 receptors found throughout the body.

In this guide, we organize knowledge about cannabinoids based on publications from PubMed, Nature, Frontiers in Pharmacology, and Cannabis and Cannabinoid Research. You will learn how the endocannabinoid system works, how individual compounds differ, what the entourage effect is, and what the legal status of these substances is in Poland in 2026.

KEY INFORMATION
– More than 150 cannabinoids have been identified in hemp; the most important are THC, CBD, CBG, CBN, CBC and THCV (PubMed, 2023).
– The endocannabinoid system (ECS) regulates sleep, appetite, mood, immune response, and pain perception.
– CB1 receptors are found mainly in the brain, CB2 in the immune and peripheral systems.
– The entourage effect is the synergy of cannabinoids with terpenes; 62% consumers choose broad-spectrum oils (Project CBD, 2023).
– CBD, CBG and other non-psychoactive cannabinoids are legal in Poland with a THC content below 0.3%.

What are cannabinoids and how do we classify them?

Cannabinoids are a group of chemical compounds that activate cannabinoid receptors in the body. We divide them into three categories: phytocannabinoids (plant-based), endocannabinoids (endogenous), and synthetic cannabinoids. Over 150 phytocannabinoids have been identified in the Cannabis sativa L. plant, and new compounds are still being discovered (PubMed, 2023).

Phytocannabinoids occur exclusively in cannabis and a few other plants. The most well-known are THC (tetrahydrocannabinol) and CBD (cannabidiol). Both molecules have the same molecular formula C21H30O2, but differ in the arrangement of atoms. This subtle difference determines whether a compound is psychoactive or not.

Endocannabinoids are compounds produced by our bodies. The two most important, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), were discovered in 1992 and 1995, respectively. They are produced on demand from fatty acids in response to specific stimuli. Anandamide takes its name from the Sanskrit word "ananda," meaning joy or bliss.

Synthetic cannabinoids are created in a laboratory. Some are registered as drugs (e.g., dronabinol, nabilone). Others, like "spice" and "K2," are dangerous psychoactive substances. Synthetic THC analogues can be up to 100 times more potent than natural THC and have been associated with serious poisoning (WHO, 2022).

Phytocannabinoids – a brief description of key compounds

THC is responsible for the psychoactive effects of cannabis. It strongly binds to the CB1 receptor in the brain, hence the euphoric effect. CBD is a non-psychoactive cannabinoid with anxiolytic and anti-inflammatory properties. CBG, called the "mother of cannabinoids," is the biochemical precursor to THC, CBD, and CBC. CBN is formed from the degradation of THC and has a mild sedative effect.

CBC (cannabichromene) shows neuroprotective potential in preclinical models. THCV (tetrahydrocannabivarin) suppresses appetite at low doses and activates CB1 at high doses. CBDV (cannabidivarin) is being studied as a potential anti-epileptic drug. Each of these compounds has a distinct pharmacological profile.

The difference between cannabinoid acids and active forms

In the living plant, cannabinoids mainly exist as acids: THCA, CBDA, CBGA. Only heating (decarboxylation) converts them into active forms THC, CBD, and CBG. Therefore, raw hemp flower acts differently than that after vaporization. CBDA and THCA have their own pharmacological effects, particularly anti-inflammatory and antiemetic (PMC, 2020).

This explains why the method of consumption matters. Eating raw extract, vaporizing, or sublingual oil provides different cannabinoid profiles in the blood. The decarboxylation temperature for THCA is around 105-120 degrees Celsius with prolonged exposure. For CBDA, the values are similar.

In the Cannabis sativa L. plant, over 150 phytocannabinoids and more than 500 other chemical compounds, including terpenes and flavonoids, have been identified (PubMed, 2023). Phytocannabinoids mimic the action of the body's endogenous endocannabinoids by activating CB1 and CB2 receptors in the ECS.

How does the endocannabinoid system (ECS) work?

The endocannabinoid system is an extensive signaling system discovered only in the 1990s. It consists of three components: cannabinoid receptors (mainly CB1 and CB2), endocannabinoids (anandamide, 2-AG), and metabolic enzymes (FAAH, MAGL). The ECS regulates the body's homeostasis and is present in all vertebrates (PMC, Frontiers in Pharmacology, 2020).

The history of the ECS discovery is fascinating. In 1988, Allyn Howlett identified the CB1 receptor in rats. Five years later, Sean Munro discovered CB2. In 1992, Raphael Mechoulam isolated anandamide, the first endogenous cannabinoid. These discoveries revealed the existence of a complete regulatory system, comparable in scale to the nervous or hormonal systems.

The ECS operates through "reverse neurotransmission." When a postsynaptic neuron receives an excessively strong signal, it produces endocannabinoids, which then flow back to the presynaptic neuron and quiet the excessive activity. This is a safety mechanism that prevents neuronal excitotoxicity.

The system regulates a wide range of biological functions. These include: appetite and metabolism, sleep and circadian rhythm, mood and anxiety, immune response, memory and learning, pain perception, body temperature, reproductive functions, and motor skills. It is hard to find a physiological process in which the ECS is not involved.

Where are the CB1 and CB2 receptors located?

CB1 receptors are most densely distributed in the central nervous system. They can be found in the hippocampus (memory), basal ganglia (motor skills), cerebral cortex (cognitive processes), hypothalamus (appetite, temperature), and cerebellum (coordination). The density of CB1 in the brain is ten times higher than that of opioid receptors (Frontiers in Pharmacology, 2020).

CB2 receptors dominate in the immune system. They can be found in the spleen, tonsils, thymus, in immune cells (B lymphocytes, macrophages), and in peripheral tissues: skin, gastrointestinal tract, and bones. This is why topical CBD cosmetics may exhibit anti-inflammatory effects.

This isn't a binary distribution. CB1 receptors are also found in the gastrointestinal tract, heart, and adipose tissue. CB2 receptors appear in the brainstem and some areas of the CNS. This bidirectional distribution explains why the ECS simultaneously influences brain function and inflammatory processes.

Endocannabinoids – anandamide and 2-AG

Anandamide (N-arachidonoylethanolamine, AEA) is derived from membrane phospholipids. It is metabolized by the FAAH enzyme (fatty acid amide hydrolase). The half-life of anandamide is only a few minutes. Therefore, the ECS operates precisely and quickly in response to stimuli.

2-AG (2-arachidonoylglycerol) is present in the body at significantly higher concentrations than anandamide. It is metabolized by the MAGL enzyme (monoacylglycerol lipase). 2-AG is the main endocannabinoid for retrograde signaling in the CNS. It is responsible for the synaptic modulation of glutamate and GABA.

Interestingly, intense physical exercise increases blood anandamide levels. The "runner's high" is largely an endocannabinoid effect, not just an endorphin effect, as previously thought (PMC, 2017). Therefore, cannabinoid supplementation may simulate the effects of regular training at the receptor level.

Unique observation: The ECS acts as an internal conductor of homeostasis. Unlike most biological systems, it does not have its own organ, nor does it have a single neurotransmitter. It functions as a distributed network in every tissue. This is why ECS disorders manifest in such diverse ways: sometimes as a migraine, other times as insomnia or irritable bowel syndrome.

What are the differences between CB1 and CB2 receptors?

CB1 and CB2 receptors are the two main cannabinoid receptors in mammals. Both belong to the GPCR family (G protein-coupled receptors), but differ in location and biological function. CB1 predominates in the CNS, while CB2 is found in the immune system. The density of CB1 in the brain is ten times higher than that of opioid receptors (Frontiers in Pharmacology, 2020).

The CB1 receptor is responsible for the psychoactivity of THC. THC binds strongly to it and mimics the action of anandamide. The euphoric effect and changes in perception result from this activation. CBD, on the other hand, binds very weakly to CB1 and acts more as an allosteric modulator. This explains the lack of psychoactive effects of CBD.

The CB2 receptor does not induce euphoria. Its activation mainly translates into modulation of the immune response and reduction of inflammation. Therefore, cannabinoids with no affinity for CB1 (like CBG) can affect inflammation without altering consciousness. This is an important feature from the perspective of therapeutic safety.

In addition to CB1 and CB2, there are "atypical" cannabinoid receptors. These include GPR55, GPR18, GPR119, and the vanilloid TRPV1 receptors. Phytocannabinoids activate them to varying degrees. CBD has a particular affinity for TRPV1 and the serotonergic 5-HT1A receptor, which explains its anxiolytic effects.

CB1 – regulator of the CNS and higher functions

CB1 regulates the release of neurotransmitters: glutamate, GABA, dopamine, serotonin, and norepinephrine. It is also involved in memory consolidation and motor skills. Inhibition of CB1 reduces appetite (hence the concept of anti-obesity drugs like rimonabant, withdrawn due to psychiatric effects).

Activation of CB1 in the hippocampus affects short-term memory. After consuming large doses of THC, one may have difficulty remembering. CBD mitigates this effect through allosteric modulation of CB1. Therefore, CBD+THC mixtures provide a milder psychoactive profile than pure THC.

CB2 – the guardian of the immune system

CB2 is found in lymphocytes, macrophages, NK cells, mast cells, and neutrophils. Activation of CB2 inhibits the production of pro-inflammatory cytokines (TNF-alpha, IL-6) and promotes the M2 macrophage phenotype, which is anti-inflammatory. This is the basis for the anti-inflammatory action of cannabinoids such as CBG.

In the skin, CB2 receptors are present in keratinocytes and sebocytes. They influence sebum production and the inflammatory response in acne. Therefore, topical applications of CBD and CBG show potential in dermatology. Studies on acne show a reduction in inflammation and regulation of lipogenesis (PMC, Journal of Clinical Investigation, 2014).

Comparison: CB1 and CB2 in numbers

CB1 has about 472 amino acids, while CB2 has about 360. The sequence homology is only 44%, meaning that drug molecules can selectively activate one receptor or the other. CB1 is mainly presynaptic, while CB2 is mainly found on immune cells. The binding constant of THC for CB1 is about 40 nM, while for CB2 it is about 36 nM.

For CBD, these values are above 1000 nM for both receptors, meaning that CBD does not bind directly to CB1 and CB2 in a pharmacologically significant way. It acts through other mechanisms: allosteric modulation, inhibition of FAAH (the enzyme that breaks down anandamide), activation of TRPV1 and 5-HT1A.

Which cannabinoids are the most important and how do they work?

Of the 150 known phytocannabinoids, seven dominate the scientific literature and therapeutic practice: THC, CBD, CBG, CBN, CBC, THCV, and CBDV. Together, they account for over 90% of the cannabinoid mass in a typical cannabis plant (Nature, 2021). Each has a distinct pharmacological profile and separate applications.

THC is the strongest psychoactive cannabinoid. It activates CB1 and induces euphoria, altered perception of time, increased appetite, and analgesic effects. In medicine, it is used for chronic pain, chemotherapy, multiple sclerosis, and anorexia in AIDS. In Poland, it is available only by prescription in the medical marijuana program.

CBD is the most versatile non-psychoactive cannabinoid. It has anxiolytic, anti-inflammatory, anticonvulsant, and neuroprotective effects. Epidiolex, the first registered CBD-based drug, received FDA approval in 2018 for treatment-resistant childhood epilepsy. The WHO in a 2018 review recognized CBD as well-tolerated in humans.

CBG is a biosynthetic precursor to other cannabinoids. In a mature plant, it occurs in amounts below 1%, but breeders have created "CBG-dominant" varieties with contents as high as 15-20%. Research indicates CBG's potential in intestinal inflammation, neuroprotection, and as a potent antibacterial agent.

CBN, CBC, and minor cannabinoids

CBN (cannabinol) is formed from the degradation of THC. Its content increases in older, oxidized cannabis. CBN has a mild sedative effect, hence its popularity as the "sleep cannabinoid." It also has a weak affinity for CB1, meaning it is mildly psychoactive in very high doses, but in practice it does not produce euphoric effects.

CBC (cannabichromene) does not strongly bind to CB1 or CB2, but activates TRPA1 and TRPV3. These receptors are involved in pain perception and thermoregulation. CBC exhibits anti-inflammatory, antidepressant effects in animal models, and neuroprotective properties. Together with CBD and CBG, it forms a triad of non-psychoactive therapeutic cannabinoids.

THCV (tetrahydrocannabivarin) is a "strange" cannabinoid. At low doses, it inhibits CB1 and reduces appetite. At high doses, it activates CB1 and may have psychoactive effects. It is being studied as a potential antidiabetic and antiobesity drug. It is found primarily in certain varieties of African hemp.

Therapeutic Effects – Research Review

CBD: reduction of anxiety in 52% of patients after 8 weeks in a 2023 study (Medical Cannabis and Cannabinoids, 2023), improvement of sleep in 66% of patients after one month of supplementation. Reduction of seizure frequency in Dravet syndrome by an average of 39% (FDA, review 2018).

CBG: in a survey of 127 users, 51% reported improved concentration, 45% reduced tension, 39% better sleep (Cannabis and Cannabinoid Research, 2021). In vitro studies showed activity against MRSA stronger than vancomycin (ACS Infectious Diseases, 2020).

Medical THC: reduction of nausea and vomiting after chemotherapy by over 50%. Reduction of spasticity in multiple sclerosis by 30%. Improvement of appetite in AIDS patients. All these indications are registered in medical marijuana programs in the EU and USA.

Cannabinoid acids – underestimated molecules

THCA, CBDA, CBGA, and other cannabinoid acids were long considered "inactive" precursors. However, more recent research demonstrates their own pharmacological effects. CBDA has a strong antiemetic effect, more potent than CBD per milligram. THCA exhibits anti-inflammatory and neuroprotective properties without psychoactivity.

CBGA is being studied as a potential inhibitor of SARS-CoV-2 in in vitro models. A study from the Journal of Natural Products (2022) showed that CBGA and CBDA bind to the virus's spike protein. These are still preliminary studies, but they open an interesting direction. Raw extracts from unburned cannabis contain these acidic forms.

Bucha data Q1 2026: Our sales database includes 68% orders for broad-spectrum CBD products, 14% for full-spectrum CBD products, 11% for CBG or CBN isolates, and 7% for hemp for vaporization. Polish customers clearly prefer "safe" formulas without THC, yet retaining the entourage effect of minorized cannabinoids.

What is the entourage effect and why does it matter?

The entourage effect is the phenomenon of synergy between cannabinoids, terpenes, and flavonoids in cannabis. The concept was described by Ben-Shabat and Mechoulam in 1998 and further developed by Russo and Guy in 2011 in the British Journal of Pharmacology (PMC, British Journal of Pharmacology, 2011). A full cannabis extract works more powerfully than the sum of its individual compounds.

The mechanism is multi-level. Cannabinoids modulate each other's affinities for receptors. CBD mitigates the psychoactivity of THC through allosteric modulation of CB1. CBG inhibits the FAAH enzyme, prolonging the action of anandamide and other cannabinoids. Terpenes, such as myrcene or beta-caryophyllene, add their own pharmacological effects.

Therefore, 62% of regular cannabinoid users choose broad-spectrum or full-spectrum oils rather than pure isolates (Project CBD, 2023). 99% CBD isolate requires higher doses to achieve the same effect as broad spectrum. This is the "less is more" paradox, meaning a smaller dose of the full extract can be more effective than a higher dose of a single ingredient.

The entourage effect also has a downside. Cannabinoids can enhance each other's adverse effects. High doses of THC with CBG may increase sedation. Therefore, dosing always starts with low doses, regardless of the type of extract.

Terpenes – the aromatic key to the entourage effect

Terpenes are aromatic compounds produced by many plants. Over 200 terpenes have been identified in cannabis, with the most important being myrcene, limonene, pinene, linalool, caryophyllene, and humulene. They are responsible for the characteristic scent of different cannabis strains. Each has its own pharmacological effect.

Myrcene has sedative effects and relaxes muscles, enhancing the effect of CBD during sleep. Limonene improves mood and has antidepressant effects. Pinene supports concentration and memory. Linalool (as in lavender) has a calming effect. Beta-caryophyllene, as the only terpene, binds directly to CB2, acting anti-inflammatory.

The terpene profile of a quality extract is declared in the certificate of analysis (COA). Check if the manufacturer publishes a full COA for each batch. Lack of a COA is a warning sign of low quality. Without terpenes, we lose a significant part of the entourage effect, despite the presence of cannabinoids.

Broad spectrum, full spectrum, and isolate

Broad spectrum contains all cannabinoids and terpenes from cannabis, but without THC. This is the safest form for those who do not want the risk of THC detection in a test (professional drivers, athletes, people in regulated professions). The entourage effect is preserved, THC eliminated.

Full spectrum contains the complete extract, including trace amounts of THC up to 0.31 TP3T. This form is considered by some researchers to be the "most natural" and most potent in terms of entourage effect. In Poland, full-spectrum products are legal if they fall within the THC limit. In practice, the difference between broad and full spectrum is subtle.

An isolate is 99% pure cannabinoid. Used in clinical studies where it is necessary to know exactly which substance produces the effect. In everyday use, isolates have a weaker effect per milligram than broad-spectrum formulas. They are suitable for individuals sensitive to other plant components or testing a specific dosing hypothesis.

The entourage effect was formalized in the work of Russo and Guy in the British Journal of Pharmacology (2011). The synergy of cannabinoids with terpenes explains why 62% of regular CBD consumers choose broad-spectrum oils instead of isolates (Project CBD, 2023). A full extract requires smaller doses for a comparable effect.

What is clinical endocannabinoid deficiency?

Clinical endocannabinoid deficiency (CECD) is a hypothesis proposed by Dr. Ethan Russo in 2004. It suggests that reduced ECS activity underlies conditions such as migraine, fibromyalgia, and irritable bowel syndrome (IBS). Russo updated and confirmed this hypothesis in 2016 (PMC, Cannabis and Cannabinoid Research, 2016).

Indirect evidence is significant. In patients with migraines, reduced levels of anandamide have been found in cerebrospinal fluid. Individuals with fibromyalgia have reduced endocannabinoid activity in serum. IBS patients show disturbances in endocannabinoid transmission in the intestines. These are three diseases without a clear structural etiology, further supporting the hypothesis of functional ECS deficiency.

What reduces ECS activity? Chronic stress, lack of physical activity, omega-3 deficiency, certain medications (e.g., statins, SSRIs), a sedentary lifestyle, and inadequate sleep. Paradoxically, excessive use of exogenous cannabinoids can also weaken the ECS by reducing the expression of CB1 and CB2 receptors.

How to support the ECS naturally? Regular physical activity (especially cardio), a diet rich in omega-3 (fish, nuts), limiting alcohol, good sleep, meditation, and massage. Phytocannabinoids from cannabis can partially supplement the deficiency of endocannabinoids, but they do not replace a healthy lifestyle.

Conditions associated with ECS dysfunction

Migraine: in studies, 40% of patients with chronic migraine report improvement after CBD supplementation (PubMed, 2020). Fibromyalgia: in a 2021 review, CBD reduced pain and improved sleep in about 50% of participants. IBS: survey studies show a reduction in gastrointestinal complaints in 38-45% of users.

The full picture is not yet clear. There is a lack of large, randomized clinical studies on CECD as a concept. The hypothesis remains a useful diagnostic model but is not an official disease entity in ICD-11. Its significance is increasing with a better understanding of the ECS as a regulatory system.

Endocannabinoids and sports and physical activity

Physical activity increases levels of anandamide and 2-AG. This is the mechanism behind the "runner's high," or the runner's euphoria after a long run. In a study by Hillard et al. (2013), 30 minutes of moderate running increased blood anandamide levels three- to four-fold. The effect persists for one to two hours after exercise.

This explains why regular exercise improves mood, sleep, and stress resistance. The ECS acts like a natural "medicine" produced by the body. People who lead a sedentary lifestyle lose this mechanism. Cannabinoid supplementation can partially compensate for inactivity, but it will never fully replace exercise.

From the Bucha editorial office: Over the last two years, we have observed that customers with migraines, fibromyalgia, and IBS make up about 28% of our regular customers purchasing CBD oil. This is significantly more than would be expected based on the epidemiology of these diseases in the general population (estimated at 8-12%). This confirms the practical value of the CECD hypothesis; people with these conditions instinctively seek ECS support.

What is the legal status of cannabinoids in Poland in 2026?

In Poland in 2026, all non-psychoactive cannabinoids from hemp (Cannabis sativa L.) are legal, provided the THC content is below 0.3%. This applies to CBD, CBG, CBN, CBC, THCV, and other minor compounds. Legal basis: Act of July 29, 2005, on counteracting drug addiction (Journal of Laws 2005 No. 179 item 1485).

THC remains a controlled substance. An exception is medical marijuana available by prescription in Poland since November 2017. Patients with specific indications (chronic pain, spasticity in multiple sclerosis, nausea after chemotherapy, treatment-resistant childhood epilepsy) can receive THC products from a doctor with additional qualifications.

The CBD product market in Poland is growing rapidly. Estimates from Fakty Konopne indicate a value of around 130 million euros in 2024, with a forecast of growth to 200 million euros by 2028 (Hemp Facts, 2024). This makes Poland one of the largest CBD markets in Central Europe.

There are product category restrictions. In Poland, CBD and other cannabinoids are typically sold as cosmetics or "collectibles" products, not as dietary supplements or medicines. This is due to the EU's status as "novel food," which requires EFSA authorization. The process has been ongoing since 2019 and is not yet complete.

What is legal and what is prohibited?

It is allowed: to buy, possess, and use CBD, CBG, CBN, and other non-psychoactive cannabinoids from hemp with THC below 0.3%. It is allowed: to sell them online and in physical stores. It is allowed: to transport them in carry-on luggage within the country. It is allowed: to cultivate hemp with a license (requires registration with the Minister of Agriculture).

You may not: possess products with THC above 0.31 TP3T without a prescription. You may not: advertise cannabinoids as medicines ("treats depression," "cures cancer"). You may not: cultivate cannabis (Cannabis indica, high-THC cannabis) without a license. You may not: import products from outside the EU without a customs declaration.

Advertising and marketing regulations

Advertising of CBD and other cannabinoids is subject to restrictions. Health claims not approved by EFSA are prohibited. Manufacturers use the language of "wellness support," omitting specific medical indications. This isn't a marketing ploy, but rather compliance with EU and Polish law.

Product labeling must include: cannabinoid content, THC content (usually "below the 0.31 TP3T limit"), country of production, expiration date, and ingredients. A Certificate of Analysis (COA) is not legally mandatory but has become the market standard. The absence of a COA indicates that the manufacturer is concealing the ingredients from the consumer.

Cannabinoids and driving

In Poland, one is not allowed to drive after consuming THC. The police can perform a drug test, and detection of THC means loss of driving license and legal consequences. CBD and other non-psychoactive cannabinoids are not detected by standard tests, but full-spectrum products with trace THC could theoretically give a false positive result.

For the safety of professional drivers and those regularly tested, broad spectrum or CBD isolates are recommended, guaranteeing 0% THC. It is advisable to keep product COA documents in case of inspection. In 2026, there are still no clear guidelines for the Polish traffic police regarding trace amounts of THC from CBD products.

How to safely use cannabinoids and dose CBD?

Typical starting doses of CBD for adults are 10-25 mg daily, increased every 3-7 days until the therapeutic effect is achieved (Project CBD, 2023). The WHO in a 2018 review recognized CBD as well-tolerated in humans at doses up to 1500 mg daily (WHO, 2018). The safety profile is high, but interactions with medications require attention.

The "start low, go slow" principle is universal. Start with the lowest dose (5-10 mg), monitor your response for 3-7 days, and increase gradually. It's pointless to start with 100 mg daily, as this won't accelerate the effects and only increases the risk of side effects. The most common are drowsiness, dry mouth, and mild dizziness.

The full effect stabilizes after 2-4 weeks of regular use. Cannabinoids are modulators of the ECS, not "stronger pills." They work by restoring homeostasis, which takes time. Patience is key to successful supplementation.

One drop of 5% oil contains about 2.5 mg of cannabinoid, 10% about 5 mg, 15% about 7.5 mg. A standard 10 ml oil has about 200 drops. A typical dose of 20 mg CBD from 5% oil is 8 drops, from 10% oil is 4 drops. Precise dosing is facilitated by graduated pipettes provided with the oils.

Forms of cannabinoid intake

Sublingual drop oils offer the fastest absorption. The effect appears in 15-45 minutes, with bioavailability reaching 13-19%. Drops allow for easy dose modulation. Hold the oil under the tongue for 60-90 seconds before swallowing for maximum absorption through the mucosal blood vessels.

Soft capsules offer a repeatable dose and convenience. The action is slower (60-120 minutes), with lower bioavailability (6-10%). This is due to the first-pass effect through the liver, where P450 enzymes metabolize a significant portion of cannabinoids. Edibles work similarly, with additional slow release.

Vaporization provides the fastest absorption, meaning effects in 2-10 minutes, with bioavailability of 30-50%. However, this form requires a device and practice. Topicals (creams, ointments) act locally, not entering the bloodstream. They are suitable for targeted recovery of joints and skin but not for systemic support.

Drug interactions

CBD and other cannabinoids inhibit cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9. This can affect the metabolism of many drugs: warfarin, statins, anticonvulsants, some antidepressants, and some cardiology medications (PMC, 2019). About 50% of drugs on the market are metabolized by CYP3A4.

Before combining cannabinoids with medications, always consult a doctor or pharmacist. If you are taking medications, separate their intake in time, meaning cannabinoids at least 2 hours before or after the medication. Monitor effects and report any changes in medication action to your doctor. Some interactions may be clinically significant.

When to avoid cannabinoids?

Pregnancy and breastfeeding: insufficient safety data, FDA advises against using CBD during these periods. Liver diseases: cannabinoids are metabolized in the liver, and caution is recommended in cases of impaired liver function. Severe mental disorders: particularly THC may exacerbate psychotic symptoms in predisposed individuals.

Children: use of CBD in children only under medical supervision (e.g., Epidiolex in treatment-resistant epilepsy). Post-transplant individuals: interactions with immunosuppressive medications. Individuals undergoing chemotherapy: cannabinoids may affect the metabolism of cytostatic drugs. In each of these cases, specialist consultation is required.

What diseases can cannabinoids support?

Cannabinoids are being studied in the context of over 100 disease entities, with the strongest evidence in epilepsy, chronic pain, spasticity, chemotherapy-induced nausea, and anxiety disorders. In 2018, the WHO recognized CBD as a substance with significant therapeutic potential and a good safety profile (WHO, 2018).

The list of conditions for which cannabinoids have documented potential includes: treatment-resistant childhood epilepsy (Epidiolex approved by the FDA), chronic neuropathic pain, spasticity in multiple sclerosis, nausea and vomiting after chemotherapy, anorexia in AIDS, anxiety disorders, insomnia, migraine, fibromyalgia, IBS, acne, Parkinson's disease, Huntington's disease.

For most of these indications, the evidence is mixed. Strong clinical evidence exists for childhood epilepsy and multiple sclerosis. Moderate for pain and anxiety. Early (mainly preclinical) for neurodegenerative and cancer diseases. There is a lack of long-term studies for many indications.

Expectations regarding cannabinoids in oncology are high, but clinical data remain limited. In vitro studies show pro-apoptotic and anti-angiogenic effects of various cannabinoids on cancer cells. However, these are experiments in vitro, not studies on patients. Cannabinoids may support oncological therapy (pain reduction, nausea, appetite improvement), but they do not replace chemotherapy.

Anxiety and depression – what does the research say?

A meta-analysis from 2020 included over 30 studies on CBD in anxiety. 52% of patients with generalized anxiety reported significant improvement after 8 weeks of supplementation (Medical Cannabis and Cannabinoids, 2023). Effective doses ranged from 25-75 mg daily. The effect is comparable to some first-line medications but with a better safety profile.

In depression, the evidence is less clear. CBD may support antidepressant therapy as an adjunct but does not replace first-line medications. In animal models, CBD acts as a rapid antidepressant by activating 5-HT1A receptors. In humans, this effect is not yet well documented in randomized clinical trials.

Chronic and neuropathic pain

Pain is one of the most researched indications for cannabinoids. A 2017 review of 27 clinical trials (National Academies of Sciences) found substantial evidence for the effectiveness of cannabinoids in chronic pain in adults. Pain reduction averaged 30–50% compared to placebo.

In Poland, medical marijuana with THC is available for patients with chronic pain resistant to other medications. CBD available over the counter may support therapy but does not replace medications. The combination of CBD+THC in registered preparations (e.g., Sativex) is used in spasticity in multiple sclerosis with good efficacy.

Sleep and insomnia

In a 2019 study, 72 patients with sleep disorders received 25-75 mg of CBD daily. After one month, 66% reported improved sleep quality (PMC, The Permanente Journal, 2019). The effect was lasting and not accompanied by significant side effects. This study is often cited in discussions about the potential of CBD in insomnia.

CBN is sometimes promoted as a "sleep cannabinoid," but the evidence is less robust than for CBD. CBN+CBD blends with added myrcene from melon or lavender take advantage of the entourage effect. In practice, 20-30 mg of CBD 1-2 hours before bed is a typical dosage for adults.

Frequently Asked Questions

What exactly are cannabinoids?

Cannabinoids are a group of chemical compounds that interact with cannabinoid receptors in the body. They are divided into phytocannabinoids (plant-based, e.g., CBD, THC, CBG), endocannabinoids (produced by the body, e.g., anandamide), and synthetic cannabinoids. In the Cannabis sativa L. plant, over 150 phytocannabinoids have been identified (PubMed, 2023).

How does the endocannabinoid system (ECS) work?

The endocannabinoid system consists of CB1 and CB2 receptors, endocannabinoids (anandamide, 2-AG), and metabolic enzymes (FAAH, MAGL). The ECS regulates the body's homeostasis: sleep, mood, appetite, immune response, and pain perception. It was discovered in the 1990s (PMC, 2020).

What are the differences between CB1 and CB2 receptors?

CB1 receptors are mainly found in the central nervous system and are responsible for the psychoactive effects of THC. CB2 receptors are mainly found in the immune system and peripheral tissues, regulating inflammation. The density of CB1 in the brain is ten times higher than that of opioid receptors (Frontiers in Pharmacology, 2020).

Are CBD and cannabinoids legal in Poland in 2026?

CBD, CBG, CBN, CBC, and other natural cannabinoids from hemp are legal in Poland, provided the THC content is below 0.3%. Legal basis: Act on Counteracting Drug Addiction (Journal of Laws 2005 No. 179 item 1485). THC remains a controlled substance outside the medical marijuana program.

What is the entourage effect (entourage effect)?

The entourage effect is the synergy between cannabinoids, terpenes, and flavonoids in cannabis. The whole extract works more powerfully than the sum of its individual compounds. The concept was described by Russo and Mechoulam in the British Journal of Pharmacology (PMC, 2011). Therefore, 62% of users prefer broad-spectrum oils (Project CBD, 2023).

What is the difference between phytocannabinoids and endocannabinoids?

Phytocannabinoids come from the cannabis plant (CBD, THC, CBG) and mimic the action of endocannabinoids. Endocannabinoids, such as anandamide and 2-AG, are produced by mammalian bodies on demand. The structure is different, but both types activate the same CB1 and CB2 receptors (Cannabis and Cannabinoid Research, 2021).

Can a deficiency of endocannabinoids cause diseases?

The clinical endocannabinoid deficiency (CECD) hypothesis suggests a link to migraine, fibromyalgia, and irritable bowel syndrome. Russo (2016) described evidence of reduced levels of anandamide in patients with these conditions (PMC, 2016). Supplementation with phytocannabinoids may partially balance this dysfunction.

How many different cannabinoids are in cannabis?

In the Cannabis sativa L. plant, over 150 phytocannabinoids have been identified, and the total number of chemical compounds exceeds 500 (PubMed, 2023). The most important include THC, CBD, CBG, CBN, CBC, THCV, and CBDV. Most occur in the plant primarily as cannabinoid acids (THCA, CBDA), which decarboxylate under heat.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: September 27, 2025
Last update: April 23, 2026